| Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs. | |
| | |
MedLine Citation:
|
PMID: 20442223 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Apolipoprotein B100 (apoB100) is an essential component of very low density lipoprotein (VLDL) and low-density lipoprotein (LDL), both independent markers of cardiovascular risk. Nicotinic acid (NA) is an efficacious drug for decreasing VLDL and LDL, but the underlying mechanisms are unclear. For this purpose, six obese insulin-resistant dogs were given 350 mg/day of NA for 1 week and then 500 mg/day for 3 weeks. Turnover of apoB100-containing lipoproteins was investigated using stable isotope-labeled tracers. Multicompartmental modeling was used to derive kinetic parameters before and at the end of NA treatment. Hepatic diacylglycerol acyltransferase 2 (DGAT2), microsomal triglyceride transfer protein (MTP), hepatic lipase (HL), and adipose lipoprotein lipase (LPL) mRNA expression was also determined. NA treatment decreased plasma triglyceride (TG) (p < 0.001), VLDL-TG (p < 0.05), total cholesterol (p < 0.0001), and LDL cholesterol (p < 0.05), whereas plasma nonesterified fatty acids were unchanged. The decrease in VLDL-apoB100 concentration (p < 0.001) was the result of a lower absolute production rate (APR) (p < 0.001), despite a moderate decrease (p < 0.05) in fractional catabolic rate (FCR). LDL-apoB100 concentration was reduced (p < 0.05), an effect related to a decrease in LDL APR (p < 0.05) and no change in FCR. NA treatment reduced DGAT2 expression (p < 0.05), whereas MTP, HL, and LPL expression was unchanged. Our results suggest that NA treatment reduced VLDL and LDL concentration as a consequence of a decrease in VLDL production. |
| | |
Authors:
|
Jérôme Le Bloc'h; Véronique Leray; Maud Chetiveaux; Benjamin Freuchet; Thierry Magot; Michel Krempf; Patrick Nguyen; Khadija Ouguerram |
Related Documents
:
|
18027813 - Genetic determinants of risk factors for cardiovascular disease in a population from ru... 3082933 - Plasma cholesterol metabolism in end-stage renal disease. difference between treatment ... 17589373 - Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinav... |
Publication Detail:
|
Type: Journal Article Date: 2010-05-04 |
Journal Detail:
|
Title: The Journal of pharmacology and experimental therapeutics Volume: 334 ISSN: 1521-0103 ISO Abbreviation: J. Pharmacol. Exp. Ther. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-19 Completed Date: 2010-08-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0376362 Medline TA: J Pharmacol Exp Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 583-9 Citation Subset: IM |
Affiliation:
|
Human Nutrition Research Center of Nantes, Nantes, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Apolipoprotein B-100 / blood* Diacylglycerol O-Acyltransferase / antagonists & inhibitors*, biosynthesis, genetics Dogs Insulin Resistance Kinetics Lipoproteins, LDL / blood Lipoproteins, VLDL / blood* Male Models, Biological Niacin / therapeutic use* Obesity / blood, drug therapy* RNA, Messenger / biosynthesis |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoprotein B-100; 0/Lipoproteins, LDL; 0/Lipoproteins, VLDL; 0/RNA, Messenger; 59-67-6/Niacin; EC 2.3.1.20/Diacylglycerol O-Acyltransferase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A claudin-targeting molecule as an inhibitor of tumor metastasis.
Next Document: The role of CD200 in immunity to B cell lymphoma.